

Q1 2020 FINANCIAL RESULTS

OUR DIVERSIFIED MODEL DELIVERED IN Q1

SALES WORLDWIDE

\$7.7B
in sales

+4.3%¹
on organic basis*

SALES PERFORMANCE ACROSS ABBOTT²

ON AN ORGANIC BASIS*



+7.3%

NUTRITION



+9.3%

ESTABLISHED
PHARMACEUTICALS



+2.9%

MEDICAL DEVICES



+0.7%

DIAGNOSTICS

HELPING TO STEM THE SPREAD OF COVID-19

DETECTING THE VIRUS

- Launched new lab-based antibody blood test, the **SARS-CoV-2 IgG** test, available now in the U.S. for the detection of the antibody that identifies if a person has had the novel coronavirus (COVID-19)
- Launched two new COVID-19 detection tests: the rapid point-of-care **ID NOW™ COVID-19** test, delivering positive results in as little as five minutes, as well as the **m2000™ RealTime SARS-CoV-2 EUA** laboratory test for hospital and reference labs
- Expect to produce millions of COVID-19 tests per month, deploying them to areas of greatest impact

SUPPORTING IMPACTED COMMUNITIES

- Donating funding and products to support frontline healthcare workers, families and communities

PROTECTING OUR EMPLOYEES

- Taken steps at our sites to limit exposure
- Further enhanced facility safety for employees working to continue to supply our vital healthcare products

OUR PRODUCT PORTFOLIO IS STRONG AND DRIVING THE FUTURE OF HEALTHCARE

**FREESTYLE
LIBRE
SALES
UP 63%³**
ON ORGANIC BASIS*

- **FreeStyle Libre 14 day system†** can now be used in hospital settings during the COVID-19 pandemic, permitting frontline healthcare workers to remotely monitor patients with diabetes receiving inpatient care, who can scan themselves
- Received expanded reimbursement in Japan to include people with Type 2 diabetes using multiple daily injections of insulin
- Announced collaboration with Insulet to create an integrated insulin delivery platform




114 mg/dL

HEART FAILURE

**SALES
UP 11%⁴**
ON ORGANIC BASIS*

- Received U.S. FDA approval for less-invasive surgical approach for heart failure patients

STRUCTURAL HEART



TriClip

CE MARK FOR TWO DEVICES TO TREAT CHALLENGING FORMS OF HEART DISEASE

- **TriClip™**, world's first minimally invasive, clip-based repair device for the treatment of tricuspid regurgitation, or leaky tricuspid valve
- **Tendyne™**, first-of-its-kind technology that treats mitral regurgitation in patients requiring a heart valve replacement, without open-heart surgery



Tendyne

* Organic sales growth excludes impact of foreign exchange. For full financial data and reconciliation of non-GAAP measures, please see our press release dated April 16, 2020, available at www.abbottinvestor.com.

† Find important safety information about the FreeStyle Libre 14 day system: <https://www.freestylelibre.us/safety-information.html>

1. On a GAAP basis, Abbott sales increased 2.5%. 2. On a GAAP basis, Nutrition sales increased 6.3%; Established Pharmaceuticals sales increased 5.2%; Medical Devices sales increased 1.4%; and Diagnostics sales decreased 0.8%. 3. On a GAAP basis, FreeStyle Libre sales increased 59%. 4. On a GAAP basis, Heart Failure sales increased 10%.

FORWARD-LOOKING STATEMENTS

Some statements in this communication may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties, including the impact of the COVID-19 pandemic on Abbott's operations and financial results, that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2019, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.